Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Cyclooxygenase in MDD
NCT04582916Phase 1Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Jul 2021
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]MC1 and [11C]PS13 in major depressive disorder (MDD) (2 arms), sponsored by National Institute of Mental Health. Primary endpoints: Calculation of COX-2 density from [11C]MC1 PET scans at 36 months and Calculation of the density of COX-1 using [11C]PS13 at 36 months. Started Jul 2021; status: recruiting.
02
Drugs
[11C]MC1[11C]PS13
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04582916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582916.